NCT/Study#

GDC-0084

A Phase 2 study of Paxalisib (GDC-0084) in recurrent or refractory Primary Central Nervous System Lymphoma (PCNSL)

A Phase 2 study of Paxalisib (GDC-0084) in recurrent or refractory Primary Central Nervous System Lymphoma (PCNSL)

DISEASE GROUP:
Neuro-Oncology
current phase:
STUDY STATUS:
Active
Location:
Hackensack, NJ
For More information: